Valeant Pharmaceuticals Receives Notice Of Default From Bondholders

May 19, 2016

Notice Does Not Accelerate Any of Valeant's Indebtedness

Company Has Until July 18, 2016 to Cure Default By Filing Form 10-Q

Company Continues to Expect to File Form 10-Q on or Before June 10, 2016

LAVAL, Quebec, May 19, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced that it has received a notice of default from the trustee under one of its senior note indentures as a result of the delay in Valeant filing its Form 10-Q for the period ended March 31, 2016. The notice of default does not result in the acceleration of any of Valeant's indebtedness.

Under its senior note indenture, Valeant has 60 days from the receipt of the notice to file the Form 10-Q, which will cure the default in all respects. As announced on May 9, 2016, Valeant expects to file the Form 10-Q with the Securities and Exchange Commission and the Canadian Securities Regulators on or before June 10, 2016, which would be well in advance of the 60-day cure date of July 18, 2016.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding the timing of filing the Company's Form 10-Q. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to

update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:

Laurie W. Little 949-461-6002

laurie.little@valeant.com

Elif McDonald 905-695-7607 elif.mcdonald@valeant.com

Media: Renée Soto or Chris Kittredge/Jared Levy Sard Verbinnen & Co. 212-687-8080

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-receives-notice-of-default-from-bondholders-300272066.html

SOURCE Valeant Pharmaceuticals International, Inc.





LEGAL NOTICE PRIVACY POLICY Investor Inquiries

ir@bauschhealth.com

EMAIL ALERTS EMAIL PAGE RSS FEED

877-281-6642 EMAIL ALERTS EMAIL PAGE RSS FEET 514-856-3855 (Canada)

the Legal Notice and Privacy Policy.

Media inquiries
© 2025 Bausch Health Companies Inc. All rights
Corporate communications@bauschbealth.com
reserved. MTB.0230.USA.18 V2.0

<u>Corporate.communications@bauschhealth.com</u> reserved. MTB.0230.USA.18 V2.0 908-569-3692

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

Use of this site signifies your agreement to

